These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 28039268)
1. Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways. Derakhshan A; Chen Z; Van Waes C Clin Cancer Res; 2017 Mar; 23(6):1379-1387. PubMed ID: 28039268 [TBL] [Abstract][Full Text] [Related]
2. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2. Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115 [TBL] [Abstract][Full Text] [Related]
3. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC. Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358 [TBL] [Abstract][Full Text] [Related]
4. Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway. Sun Q; Zheng X; Zhang L; Yu J Clin Cancer Res; 2011 Apr; 17(8):2361-72. PubMed ID: 21242120 [TBL] [Abstract][Full Text] [Related]
5. The expanding role of IAP antagonists for the treatment of head and neck cancer. Kansal V; Kinney BLC; Uppada S; Saba NF; Stokes WA; Buchwald ZS; Schmitt NC Cancer Med; 2023 Jul; 12(13):13958-13965. PubMed ID: 37132167 [TBL] [Abstract][Full Text] [Related]
6. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma. Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848 [TBL] [Abstract][Full Text] [Related]
7. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686 [TBL] [Abstract][Full Text] [Related]
8. Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10. Raulf N; El-Attar R; Kulms D; Lecis D; Delia D; Walczak H; Papenfuss K; Odell E; Tavassoli M Br J Cancer; 2014 Nov; 111(10):1955-64. PubMed ID: 25314064 [TBL] [Abstract][Full Text] [Related]
9. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830 [TBL] [Abstract][Full Text] [Related]
10. Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Tchoghandjian A; Jennewein C; Eckhardt I; Rajalingam K; Fulda S Cell Death Dis; 2013 Mar; 4(3):e564. PubMed ID: 23538445 [TBL] [Abstract][Full Text] [Related]
11. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma. Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis. Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059 [TBL] [Abstract][Full Text] [Related]
13. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas. An Y; Jeon J; Sun L; Derakhshan A; Chen J; Carlson S; Cheng H; Silvin C; Yang X; Van Waes C; Chen Z Sci Rep; 2021 Mar; 11(1):6392. PubMed ID: 33737574 [TBL] [Abstract][Full Text] [Related]
14. Bypass NFkappaB-mediated survival pathways by TRAIL and Smac. Ren X; Xu Z; Myers JN; Wu X Cancer Biol Ther; 2007 Jul; 6(7):1031-5. PubMed ID: 17611406 [TBL] [Abstract][Full Text] [Related]
15. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078 [TBL] [Abstract][Full Text] [Related]
16. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Petersen SL; Peyton M; Minna JD; Wang X Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11936-41. PubMed ID: 20547836 [TBL] [Abstract][Full Text] [Related]
17. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Ng CP; Bonavida B Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428 [TBL] [Abstract][Full Text] [Related]
18. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition. Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589 [TBL] [Abstract][Full Text] [Related]
19. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma. Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656 [TBL] [Abstract][Full Text] [Related]